Executive Summary
Both BNB Plus Corp. and SurgePays, Inc. disclosed Nasdaq notifications for failing minimum listing standards, signaling acute delisting risks on the Nasdaq Capital Market amid chronically low bid prices below $1.00. BNB Plus is ineligible for a standard compliance period due to prior reverse stock splits totaling a 250:1 ratio over the past two years, while SurgePays has 180 calendar days to cure MVLS ($35M) and bid price deficiencies but faces immediate dilution from issuing 800,000 shares to CEO Brian Cox at $1.25/share to settle a $1M promissory note. No positive period-over-period financial trends evident; implied QoQ stock price deterioration with BNBX bid < $1 for 30 consecutive days (Feb 5-Mar 19, 2026) and SurgePays similarly deficient. Cross-filing pattern reveals 2/2 companies at Materiality 9/10 negative sentiment, highlighting systemic small-cap distress on Nasdaq. Forward-looking catalysts include BNB's planned hearing request and SurgePays' compliance deadlines in September 2026, but no assurance of listing retention. Portfolio-level implication: Heightened volatility and liquidity risks for Nasdaq small caps, urging avoidance or short strategies.
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from March 23, 2026.
Investment Signals(12)
- BNB PLUS CORP↓(BEARISH)▲
Failed Nasdaq $1.00 minimum bid price for 30 consecutive business days (Feb 5-Mar 19, 2026), triggering notification under Rule 5550(a)(2)
- BNB PLUS CORP↓(BEARISH)▲
Ineligible for compliance period per Rule 5810(c)(3)(A) due to cumulative prior reverse splits (250:1 ratio in past 2 years), highest delisting urgency
- SurgePays, Inc.↓(BEARISH)▲
Failed $35M MVLS requirement (notice Mar 18, 2026) and $1.00 bid price (notice Mar 23, 2026), 180 days to comply vs no extension for BNB
- SurgePays, Inc.↓(BEARISH)▲
Issued 800,000 common shares to CEO Brian Cox at $1.25/share under Reg D Rule 506(b), diluting shareholders to settle $1M debt
- BNB PLUS CORP↓(BEARISH)▲
Plans hearing request before Nasdaq Hearings Panel, but explicitly 'no assurance' of continued listing, lower conviction than SurgePays' cure window
- SurgePays, Inc.↓(BEARISH)▲
CEO share issuance increases insider holdings but signals cash constraints, no buybacks/dividends noted amid compliance failures
- BNB PLUS CORP vs SurgePays↓(BEARISH)▲
BNB's reverse split history (250:1) worse than SurgePays' fresh notices, indicating relative underperformance in stock price maintenance
- SurgePays, Inc.↓(NEUTRAL)▲
Potential for additional 180-day bid price extension if other criteria met, slight relative outperformance vs BNB's ineligibility
- BNB PLUS CORP↓(BEARISH)▲
Headquartered in Stony Brook, NY health sciences hub, but no operational metrics shared amid listing crisis
- SurgePays, Inc.↓(BEARISH)▲
Restrictive legend on new shares limits liquidity, compounding MVLS deficiency risks
- Cross-Company(BEARISH)▲
2/2 filings show bid price < $1 over extended periods, no YoY/QoQ revenue or margin data to offset, pure valuation distress
- SurgePays, Inc.↓(NEUTRAL)▲
Debt settlement via equity avoids immediate cash outflow, preserving liquidity for compliance efforts
Risk Flags(10)
- BNB PLUS CORP / Delisting Risk↓[HIGH RISK]▼
Immediate Nasdaq hearing required, ineligible for cure period due to 250:1 reverse splits past 2 years
- SurgePays, Inc. / MVLS Failure↓[HIGH RISK]▼
$35M threshold breached (Mar 18 notice), compliance deadline Sept 14, 2026; failure reduces liquidity
- SurgePays, Inc. / Bid Price Failure↓[HIGH RISK]▼
< $1.00 for deficient period (Mar 23 notice), deadline Sept 21, 2026; hinders financing/equity incentives
- BNB PLUS CORP / Prior Reverse Splits↓[HIGH RISK]▼
Cumulative 250:1 ratio disqualifies standard compliance, chronic stock price weakness implied
- SurgePays, Inc. / Share Dilution↓[MEDIUM-HIGH RISK]▼
800k shares issued to CEO, direct shareholder value erosion amid MVLS pressure
- BNB PLUS CORP / Hearing Uncertainty↓[HIGH RISK]▼
Planned request but 'no assurance' of panel approval, potential trading suspension imminent
- SurgePays, Inc. / Regulatory Overlap↓[HIGH RISK]▼
Dual notices (MVLS + bid price) within 5 days, compounded compliance burden vs single-issue peers
- Cross-Company / Liquidity[HIGH RISK]▼
Both face potential delisting reducing liquidity, no capital allocation (dividends/buybacks) to support price
- BNB PLUS CORP / Ticker BNBX↓[MEDIUM RISK]▼
Nasdaq Capital Market exposure heightens volatility on delisting path
- SurgePays, Inc. / Insider Debt↓[MEDIUM-HIGH RISK]▼
$1M promissory note settled via equity signals cash flow strain, no forward operational metrics to reassure
Opportunities(10)
- BNB PLUS CORP / Hearing Appeal↓(OPPORTUNITY)◆
Request to Nasdaq Panel could delay delisting; monitor for stay or plan, potential short squeeze if positive
- SurgePays, Inc. / Compliance Window↓(OPPORTUNITY)◆
180 days to Sept 14/21, 2026 for MVLS/bid price; success restores listing, possible extension if criteria met
- SurgePays, Inc. / CEO Alignment↓(OPPORTUNITY)◆
Insider share issuance (800k at $1.25) boosts CEO holdings, incentivizing compliance efforts
- BNB PLUS CORP / Reverse Split Precedent↓(OPPORTUNITY)◆
History shows management action (250:1 splits); panel may grant exception despite ineligibility
- SurgePays, Inc. / Reg D Flexibility↓(OPPORTUNITY)◆
Shares under 4(a)(2)/506(b) avoid immediate public float dilution, buys time for turnaround
- Cross-Company / Short Bias(OPPORTUNITY)◆
Both at 9/10 materiality negative; delisting catalysts offer alpha via shorts or puts pre Sept 2026
- SurgePays, Inc. / Debt Cleanup↓(OPPORTUNITY)◆
$1M note settled preserves cash for bid price support (e.g., buybacks if viable)
- BNB PLUS CORP / Health Sciences Niche↓(OPPORTUNITY)◆
Stony Brook HQ positioning for potential acquisition/partner post-crisis resolution
- SurgePays, Inc. / Relative Strength↓(OPPORTUNITY)◆
Longer cure period vs BNB positions for outperformance if market rebounds
- Cross-Company / Volatility Play(OPPORTUNITY)◆
Pre-compliance deadlines offer options trading alpha on halt/suspension risks
Sector Themes(6)
- Nasdaq Bid Price Distress◆
2/2 companies failed $1.00 rule over 30+ days, implying broad small-cap price decay; raises sector delisting wave risk
- MVLS + Bid Price Combo◆
SurgePays dual failures (1/2 filings) vs BNB single; signals deepening valuation crisis for Nasdaq Capital Market names
- Reverse Split Chronicity◆
BNB's 250:1 past 2 years (1/2) highlights repeated interventions failing, pattern for microcaps avoiding OTC downgrade
- Equity-for-Debt Dilution◆
SurgePays CEO issuance amid crisis (1/2); trend in cash-strapped small caps prioritizing survival over dilution avoidance
- Compliance Deadline Clustering◆
Sept 2026 deadlines (SurgePays); synchronizes risk events, potential sector-wide suspensions if unmet
- Negative Sentiment Uniformity◆
2/2 at 9/10 materiality/negative, no forward guidance offsets; eroding investor conviction in Nasdaq small caps
Watch List(8)
Planned request post-Mar 20, 2026 notice; watch for panel date/decision on listing stay [TBD 2026]
Monitor market value regain efforts; deadline Sept 14, 2026 or face delisting [Sept 14, 2026]
Track $1.00 threshold; initial deadline Sept 21, 2026, possible extension [Sept 21, 2026]
Post-notice trades/pledges; gauge conviction amid ineligibility [Ongoing]
Changes in Brian Cox post-800k issuance; dilution impact on MVLS [Ongoing]
Any new announcements building on 250:1; signals distress escalation [Q2 2026]
- Cross-Company / Trading Halts👁
SEC/Nasdaq suspensions tied to delisting paths [Mar-Apr 2026]
New debt/equity raises under Reg D to support compliance [Pre-Sept 2026]
Filing Analyses(2)
24-03-2026
BNB Plus Corp. received a Nasdaq notification letter on March 20, 2026, indicating failure to satisfy the $1.00 minimum bid price rule (Listing Rule 5550(a)(2)) over 30 consecutive business days from February 5 to March 19, 2026. The Company is ineligible for a compliance period due to prior reverse stock splits (cumulative ratio of 250:1 or more in the past two years) and plans to request a hearing before the Nasdaq Hearings Panel, with no assurance of continued listing. This raises significant delisting risk for its common stock (ticker: BNBX).
- ·Nasdaq Listing Rules cited: 5550(a)(2) and 5810(c)(3)(A)
- ·Securities traded on Nasdaq Capital Market under ticker BNBX
- ·Company headquartered at 25 Health Sciences Drive, Stony Brook, New York 11790
24-03-2026
SurgePays, Inc. received Nasdaq notices on March 18 and 23, 2026, for failing the $35M minimum market value of listed securities (MVLS) requirement and the $1.00 minimum bid price requirement, with 180 days to regain compliance or face delisting. The company issued 800,000 shares of common stock to CEO Brian Cox at $1.25 per share to settle a $1M promissory note debt. No immediate trading suspension, but failure to comply could reduce liquidity, hinder financing, and limit equity incentives.
- ·MVLS compliance period ends September 14, 2026 (180 calendar days from March 18, 2026)
- ·Bid Price compliance period ends September 21, 2026 (180 calendar days from March 23, 2026); potential for additional 180 days if other criteria met
- ·Shares issued under Section 4(a)(2) and Rule 506(b) of Regulation D with restrictive legend
- ·Potential delisting impacts include reduced stock liquidity/market price, fewer investors, limited public capital access, and impaired employee equity incentives
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 2 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)